EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer

SIMPLE SUMMARY: Malignant Head and neck squamous cell carcinomas occur frequently, and several treatment regimens are used to fight disease progression. While anti-Epidermal growth factor receptor (EGFR) antibody cetuximab is applied successfully in many cases, therapy resistance occurs after a shor...

Descripción completa

Detalles Bibliográficos
Autores principales: Cserepes, Mihály, Nelhűbel, Györgyi A., Meilinger-Dobra, Mónika, Herczeg, Adrienn, Türk, Dóra, Hegedűs, Zita, Svajda, Laura, Rásó, Erzsébet, Ladányi, Andrea, Csikó, Kristóf György, Kenessey, István, Szöőr, Árpád, Vereb, György, Remenár, Éva, Tóvári, József
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140151/
https://www.ncbi.nlm.nih.gov/pubmed/35626010
http://dx.doi.org/10.3390/cancers14102407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140151/
https://www.ncbi.nlm.nih.gov/pubmed/35626010
http://dx.doi.org/10.3390/cancers14102407

Ejemplares similares